{"gene":"MSS51","run_date":"2026-06-10T02:59:51","timeline":{"discoveries":[{"year":1990,"finding":"The yeast Mss51 gene product is specifically required for translation of the COX1 mRNA in yeast mitochondria; it is not merely a splicing factor but a translational activator of COX1.","method":"Genetic analysis of mss51 mutants; paromomycin-resistance mutation in 15S mitoribosomal RNA interferes with Mss51 action, linking it to the ribosome","journal":"Molecular & general genetics : MGG","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational genetic loss-of-function study replicated and built upon by multiple independent labs","pmids":["2177521"],"is_preprint":false},{"year":2009,"finding":"Yeast Mss51 has dual functions: it acts as a translational activator of COX1 mRNA (via the 5'-UTR) AND physically associates with newly synthesized, unassembled Cox1 protein in early cytochrome c oxidase assembly intermediates, thereby coupling Cox1 synthesis with CcO assembly. Sequestration of Mss51 in assembly intermediates limits its availability for translation. Cox14 is required for stable interaction of Mss51 with newly synthesized Cox1; without Cox14, Mss51 is not sequestered and Cox1 synthesis is not reduced even when CcO assembly fails.","method":"Genetic reporter assays at COX1 locus in mitochondrial DNA; co-immunoprecipitation of Mss51 with Cox1 assembly intermediates; epistasis analysis with cox14 mutants","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, genetic epistasis, reporter assays, replicated by independent labs","pmids":["19710419"],"is_preprint":false},{"year":2010,"finding":"Cox25 (a new inner mitochondrial membrane protein with matrix-facing hydrophilic C-terminus) is an essential component of the Cox1–Ssc1–Mss51–Cox14 complex that stabilizes newly synthesized Cox1 in yeast. Cox25 also interacts with Shy1 and Cox5 in a separate complex lacking Mss51, suggesting it bridges the Mss51-containing stabilization complex and later CcO assembly intermediates after Ssc1-Mss51 are released.","method":"Co-immunoprecipitation of Cox25 with Mss51, Ssc1, Cox14, Cox1; genetic analysis of cox25 null mutants; fractionation showing Cox25 is an intrinsic inner membrane protein","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with multiple partners, genetic epistasis, subcellular fractionation, independent lab confirmation of the Cox1–Mss51 complex","pmids":["21068384"],"is_preprint":false},{"year":2015,"finding":"Mammalian MSS51 (ZMYND17) localizes to the mitochondria in human skeletal muscle. CRISPR/Cas9-mediated disruption of Mss51 in C2C12 myoblasts increased cellular ATP levels, β-oxidation, glycolysis, and oxidative phosphorylation, indicating that mammalian Mss51 acts as an inhibitor of mitochondrial metabolism in skeletal muscle. Mss51 expression is upregulated upon myoblast differentiation and is downregulated by myostatin/TGF-β1 inhibition.","method":"Subcellular fractionation + immunoblot for localization; CRISPR/Cas9 KO in C2C12 cells; metabolic assays (ATP, β-oxidation, glycolysis, oxidative phosphorylation); qRT-PCR","journal":"Journal of neuromuscular diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by fractionation + CRISPR KO with metabolic readouts, single lab, two orthogonal methods","pmids":["26634192"],"is_preprint":false},{"year":2018,"finding":"Genetic inactivation of Zmynd17 (MSS51) in mice causes morphological and functional abnormalities in skeletal muscle mitochondria, resulting in decreased respiratory function. Zmynd17 deficiency exacerbates high-fat-diet-induced hepatic steatosis, glucose intolerance, and insulin resistance, and impairs aerobic exercise performance in middle-aged mice, establishing Zmynd17 as a regulator of muscle mitochondrial quality.","method":"Genetic KO mouse model; electron microscopy of mitochondrial morphology; mitochondrial respiration assays; metabolic phenotyping (glucose tolerance, insulin tolerance, high-fat diet challenge)","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with multiple orthogonal phenotypic readouts (morphology, respiration, metabolic tests), replicated by independent labs","pmids":["29913553"],"is_preprint":false},{"year":2019,"finding":"In vivo deletion of Mss51 in mice increases myofiber oxygen consumption rate, enhances expression of oxidative phosphorylation and fatty acid β-oxidation genes in skeletal muscle, and confers resistance to diet-induced obesity with increased whole-body glucose turnover, glycolysis, insulin sensitivity, and fatty acid β-oxidation, confirming MSS51 as an inhibitor of skeletal muscle mitochondrial respiration and whole-body metabolism.","method":"CRISPR/Cas9 KO mouse; Seahorse oxygen consumption rate assay; high-fat diet metabolic challenge; hyperinsulinemic-euglycemic clamp; gene expression profiling","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with multiple orthogonal metabolic assays, independent lab replication of metabolic inhibitory role","pmids":["31527314"],"is_preprint":false},{"year":2019,"finding":"Zmynd17-deficient mouse limb muscles show abnormal mitochondrial morphology that is rescued by voluntary exercise, but PGC1α overexpression in Zmynd17-KO muscle further worsens mitochondrial morphology abnormalities (also rescued by exercise). This epistasis indicates that exercise-induced mitochondrial quality control and PGC1α-induced mitochondrial biogenesis operate independently of Zmynd17.","method":"Genetic KO mouse; PGC1α overexpression; voluntary exercise intervention; electron microscopy of mitochondrial morphology; epistasis analysis","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo with morphological readout, single lab","pmids":["31921843"],"is_preprint":false},{"year":2021,"finding":"Human ZMYND17 deletion in human cells did not affect mitochondrial translation but led to decreased cytochrome c oxidase activity and increased amounts of free F1 subunit of ATP synthase, demonstrating that the human ortholog has diverged from yeast Mss51 and no longer functions as a mitochondrial translational activator.","method":"ZMYND17 gene deletion in human cells; measurement of mitochondrial translation products; cytochrome c oxidase activity assay; assessment of ATP synthase F1 subunit","journal":"Biochemistry. Biokhimiia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct KO with enzymatic activity assay and protein complex analysis, single lab, two orthogonal methods","pmids":["34565318"],"is_preprint":false},{"year":2023,"finding":"Site-1 protease (S1P) is a negative regulator of Mss51 expression in mouse skeletal muscle. S1P disruption reduces Mss51 expression and increases muscle mass and mitochondrial respiration; overexpression of Mss51 in S1P-deficient muscle counteracts the increase in mitochondrial respiration, placing Mss51 downstream of S1P in a TGF-β1 signaling axis that inhibits skeletal muscle mitochondrial respiration.","method":"Muscle-specific S1P KO mouse; Mss51 overexpression rescue experiment; mitochondrial respiration assays; gene expression analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with rescue experiment in vivo, single lab, two orthogonal methods","pmids":["37002920"],"is_preprint":false},{"year":2024,"finding":"YTHDF2 binds to MSS51 mRNA (shown by RNA immunoprecipitation) and reduces MSS51 expression in granulosa cells of PCOS patients. Reduction of MSS51 expression leads to mitochondrial damage, reduced ATP levels, increased ROS, and reduced expression of glycolysis genes (LDHA, PFKP, PKM), establishing a YTHDF2→MSS51 regulatory axis controlling mitochondrial function and glycolysis in granulosa cells.","method":"RNA immunoprecipitation (RIP) assay demonstrating YTHDF2 binding to MSS51 mRNA; YTHDF2 overexpression and MSS51 knockdown in granulosa cells; ATP/ROS measurement; immunofluorescence; Western blot","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP demonstrating direct mRNA binding, loss-of-function with metabolic readouts, single lab","pmids":["38830447"],"is_preprint":false},{"year":2024,"finding":"Betaine transcriptionally represses Mss51 expression via the transcription factor Yin Yang 1 (YY1), which directly binds the Mss51 promoter. In C2C12 cells, betaine restores Mss51-mediated suppression of mitochondrial respiration proteins and attenuates oxygen consumption impairment. In aged mice, AAV-mediated Mss51 overexpression recapitulates mitochondrial dysfunction, confirming Mss51 as a suppressor of mitochondrial respiration regulated by YY1.","method":"Luciferase reporter assay; chromatin immunoprecipitation (ChIP); electrophoretic mobility shift assay (EMSA); AAV overexpression in vivo; Seahorse assay; Western blot","journal":"Journal of cachexia, sarcopenia and muscle","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (ChIP, EMSA, luciferase reporter, in vivo AAV rescue) in single study confirming YY1→Mss51 transcriptional axis","pmids":["39187977"],"is_preprint":false},{"year":2024,"finding":"In yeast, Mss51 (like Pet309) stably associates with the mitoribosome independently of the presence of COX1 mRNA or of Pet309, indicating that translational activation of COX1 mRNA involves stable ribosome interaction rather than purely mRNA-dependent recruitment. No direct interaction of Mss51 with COX1 mRNA was detected.","method":"Co-purification/co-sedimentation of Mss51 and Pet309 with mitoribosome; genetic experiments removing COX1 mRNA or each activator; domain analysis of Pet309 N-terminal domain","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical ribosome association assay with genetic controls, preprint, single lab","pmids":["bio_10.1101_2024.11.01.621605"],"is_preprint":true}],"current_model":"MSS51/ZMYND17 encodes a protein whose yeast ortholog (Mss51p) functions as a COX1 mRNA translational activator that stably associates with the mitoribosome and couples Cox1 synthesis to cytochrome c oxidase assembly by physically interacting with newly synthesized Cox1 in a complex with Cox14, Cox25, and Ssc1—sequestration in this complex limits translation; the mammalian protein (ZMYND17) has diverged from this translational activator role and instead localizes to skeletal muscle mitochondria where it acts as an inhibitor of mitochondrial respiration, β-oxidation, and glycolysis, regulated transcriptionally by the YY1–betaine axis and post-transcriptionally by YTHDF2, and positioned downstream of TGF-β/myostatin/S1P signaling."},"narrative":{"mechanistic_narrative":"MSS51 is a mitochondrial protein whose function has diverged sharply between yeast and mammals while retaining a central role in cytochrome c oxidase (CcO) biology [PMID:2177521, PMID:26634192]. In yeast, Mss51 is a translational activator of the mitochondrially encoded COX1 mRNA acting through its 5'-UTR, and it concurrently binds newly synthesized, unassembled Cox1 protein in early CcO assembly intermediates—coupling Cox1 synthesis to assembly such that sequestration of Mss51 in these intermediates limits its availability for further translation [PMID:2177521, PMID:19710419]. This Cox1-stabilizing complex includes Cox14, Ssc1, and the inner-membrane protein Cox25, with Cox14 required for stable Mss51–Cox1 association and Cox25 bridging the Mss51-containing complex to later assembly steps involving Shy1 and Cox5 [PMID:19710419, PMID:21068384]. The mammalian ortholog (ZMYND17) has lost the translational-activator role—its deletion in human cells does not affect mitochondrial translation but reduces CcO activity—and instead localizes to skeletal-muscle mitochondria where it acts as an inhibitor of mitochondrial respiration, β-oxidation, glycolysis, and oxidative phosphorylation [PMID:26634192, PMID:34565318]. In vivo, Mss51 loss enhances myofiber oxygen consumption and oxidative gene expression and confers resistance to diet-induced obesity, insulin resistance, and hepatic steatosis, establishing it as a brake on muscle mitochondrial metabolism and whole-body energetics [PMID:29913553, PMID:31527314]. Mss51 expression is controlled transcriptionally by YY1, which directly binds its promoter and is repressed by betaine [PMID:39187977], and post-transcriptionally by YTHDF2 binding to MSS51 mRNA [PMID:38830447], and the protein is positioned downstream of TGF-β1/myostatin and Site-1 protease (S1P) signaling that suppresses muscle mitochondrial respiration [PMID:26634192, PMID:37002920].","teleology":[{"year":1990,"claim":"Established that the yeast Mss51 gene product is a dedicated translational activator of mitochondrial COX1 mRNA rather than a splicing factor, defining its founding molecular role.","evidence":"Genetic analysis of mss51 mutants, with a paromomycin-resistance mutation in 15S mitoribosomal RNA linking Mss51 to the ribosome","pmids":["2177521"],"confidence":"High","gaps":["Did not define the physical partners of Mss51","Mechanism of ribosome engagement not resolved"]},{"year":2009,"claim":"Resolved how Mss51 couples Cox1 synthesis to assembly by showing it both activates COX1 translation and binds newly made Cox1, with Cox14 required to sequester it and limit further translation.","evidence":"Reporter assays at the COX1 locus, co-immunoprecipitation of Mss51 with Cox1 assembly intermediates, and cox14 epistasis in yeast","pmids":["19710419"],"confidence":"High","gaps":["Full subunit composition of the stabilization complex incomplete","Stoichiometry and release mechanism unknown"]},{"year":2010,"claim":"Identified Cox25 as an essential member of the Cox1–Ssc1–Mss51–Cox14 stabilization complex and showed it bridges to later CcO assembly intermediates.","evidence":"Reciprocal Co-IP of Cox25 with Mss51, Ssc1, Cox14, Cox1, plus cox25 genetics and fractionation in yeast","pmids":["21068384"],"confidence":"High","gaps":["Timing of Ssc1–Mss51 release not directly observed","Structural arrangement of the complex unresolved"]},{"year":2015,"claim":"Showed the mammalian ortholog acts as a metabolic inhibitor rather than a translational activator, localizing to muscle mitochondria and restraining respiration, β-oxidation, and glycolysis.","evidence":"Subcellular fractionation, CRISPR/Cas9 KO in C2C12 myoblasts with ATP, β-oxidation, glycolysis and OXPHOS assays, and qRT-PCR","pmids":["26634192"],"confidence":"Medium","gaps":["Molecular mechanism of metabolic inhibition not defined","Single lab, two orthogonal methods","No direct molecular partners identified in mammals"]},{"year":2018,"claim":"Established Mss51 as an in vivo regulator of muscle mitochondrial quality whose loss alters mitochondrial morphology and respiration and influences systemic metabolism.","evidence":"Zmynd17 KO mouse with electron microscopy, respiration assays, and metabolic phenotyping under high-fat diet","pmids":["29913553"],"confidence":"High","gaps":["Mechanism linking Mss51 to mitochondrial morphology unclear","Direct molecular target unidentified"]},{"year":2019,"claim":"Confirmed Mss51 as a brake on muscle mitochondrial respiration and whole-body metabolism, and showed exercise- and PGC1α-driven mitochondrial pathways act independently of it.","evidence":"CRISPR KO mice with Seahorse OCR, hyperinsulinemic-euglycemic clamp, high-fat diet challenge, PGC1α overexpression and exercise epistasis","pmids":["31527314","31921843"],"confidence":"High","gaps":["Biochemical mechanism of respiration suppression unresolved","How Mss51 intersects mitochondrial quality control unknown"]},{"year":2021,"claim":"Demonstrated functional divergence of the human ortholog from yeast: its loss does not affect mitochondrial translation but lowers CcO activity and raises free ATP synthase F1.","evidence":"ZMYND17 deletion in human cells with measurement of translation products, CcO activity, and ATP synthase F1 assessment","pmids":["34565318"],"confidence":"Medium","gaps":["Mechanism linking ZMYND17 to CcO activity unknown","Single lab","Whether it physically contacts CcO not tested"]},{"year":2024,"claim":"Defined upstream regulators of mammalian Mss51—transcriptional repression by YY1/betaine and post-transcriptional control by YTHDF2—and confirmed its suppression of mitochondrial respiration in vivo.","evidence":"ChIP/EMSA/luciferase and AAV overexpression in muscle (YY1/betaine); RNA immunoprecipitation and knockdown in PCOS granulosa cells (YTHDF2)","pmids":["39187977","38830447"],"confidence":"High","gaps":["How these inputs are integrated in vivo unclear","Direct effector of Mss51 on respiratory machinery still unidentified"]},{"year":2024,"claim":"Placed mammalian Mss51 downstream of S1P/TGF-β1 signaling controlling muscle mass and respiration.","evidence":"Muscle-specific S1P KO mouse with Mss51 overexpression rescue and respiration assays","pmids":["37002920"],"confidence":"Medium","gaps":["Direct molecular link between S1P signaling and Mss51 expression not defined","Single lab, rescue-based epistasis"]},{"year":2024,"claim":"Refined the yeast translational-activation model by showing Mss51 stably associates with the mitoribosome independently of COX1 mRNA or Pet309, rather than via mRNA-dependent recruitment.","evidence":"Co-sedimentation of Mss51 and Pet309 with mitoribosome plus genetic removal of COX1 mRNA/activators (preprint)","pmids":["bio_10.1101_2024.11.01.621605"],"confidence":"Medium","gaps":["Preprint, single lab","No direct Mss51–COX1 mRNA interaction detected","Structural basis of ribosome binding unknown"]},{"year":null,"claim":"The direct molecular effector through which mammalian MSS51/ZMYND17 inhibits mitochondrial respiration and metabolism remains undefined.","evidence":"No discovery in the corpus identifies a mammalian binding partner or biochemical mechanism for metabolic suppression","pmids":[],"confidence":"Medium","gaps":["No mammalian physical interactor identified","No structural model of the divergent mammalian protein","Mechanistic link between CcO activity change and metabolic phenotype unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0045182","term_label":"translation regulator activity","supporting_discovery_ids":[0,1,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,5,7]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[2,3,4]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,4,5]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[4,6]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1]}],"complexes":["Cox1–Ssc1–Mss51–Cox14–Cox25 assembly/stabilization complex","mitoribosome (associated)"],"partners":["COX1","COX14","COX25","SSC1","PET309","YY1","YTHDF2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q4VC12","full_name":"Putative protein MSS51 homolog, mitochondrial","aliases":["Zinc finger MYND domain-containing protein 17"],"length_aa":460,"mass_kda":51.3,"function":"","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q4VC12/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MSS51","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MSS51","total_profiled":1310},"omim":[{"mim_id":"621553","title":"GTP-BINDING PROTEIN 8; GTPBP8","url":"https://www.omim.org/entry/621553"},{"mim_id":"614773","title":"MSS51 MITOCHONDRIAL TRANSLATIONAL ACTIVATOR; MSS51","url":"https://www.omim.org/entry/614773"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Vesicles","reliability":"Uncertain"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"skeletal muscle","ntpm":244.5}],"url":"https://www.proteinatlas.org/search/MSS51"},"hgnc":{"alias_symbol":["FLJ39565"],"prev_symbol":["ZMYND17"]},"alphafold":{"accession":"Q4VC12","domains":[{"cath_id":"-","chopping":"43-148","consensus_level":"medium","plddt":93.5748,"start":43,"end":148}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q4VC12","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q4VC12-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q4VC12-F1-predicted_aligned_error_v6.png","plddt_mean":87.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MSS51","jax_strain_url":"https://www.jax.org/strain/search?query=MSS51"},"sequence":{"accession":"Q4VC12","fasta_url":"https://rest.uniprot.org/uniprotkb/Q4VC12.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q4VC12/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q4VC12"}},"corpus_meta":[{"pmid":"2177521","id":"PMC_2177521","title":"The MSS51 gene product is required for the translation of the COX1 mRNA in yeast mitochondria.","date":"1990","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/2177521","citation_count":84,"is_preprint":false},{"pmid":"19710419","id":"PMC_19710419","title":"Dual functions of Mss51 couple synthesis of Cox1 to assembly of cytochrome c oxidase in Saccharomyces cerevisiae mitochondria.","date":"2009","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/19710419","citation_count":79,"is_preprint":false},{"pmid":"21068384","id":"PMC_21068384","title":"Cox25 teams up with Mss51, Ssc1, and Cox14 to regulate mitochondrial cytochrome c oxidase subunit 1 expression and assembly in Saccharomyces cerevisiae.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21068384","citation_count":68,"is_preprint":false},{"pmid":"26634192","id":"PMC_26634192","title":"Mammalian Mss51 is a skeletal muscle-specific gene modulating cellular metabolism.","date":"2015","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26634192","citation_count":32,"is_preprint":false},{"pmid":"21531385","id":"PMC_21531385","title":"ANXA7, PPP3CB, DNAJC9, and ZMYND17 genes at chromosome 10q22 associated with the subgroup of schizophrenia with deficits in attention and executive function.","date":"2011","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21531385","citation_count":25,"is_preprint":false},{"pmid":"31527314","id":"PMC_31527314","title":"Mss51 deletion enhances muscle metabolism and glucose homeostasis in mice.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31527314","citation_count":23,"is_preprint":false},{"pmid":"29913553","id":"PMC_29913553","title":"Zmynd17 controls muscle mitochondrial quality and whole-body metabolism.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29913553","citation_count":21,"is_preprint":false},{"pmid":"39187977","id":"PMC_39187977","title":"Betaine delays age-related muscle loss by mitigating Mss51-induced impairment in mitochondrial respiration via Yin Yang1.","date":"2024","source":"Journal of cachexia, sarcopenia and muscle","url":"https://pubmed.ncbi.nlm.nih.gov/39187977","citation_count":12,"is_preprint":false},{"pmid":"31921843","id":"PMC_31921843","title":"Distinct Roles of Zmynd17 and PGC1α in Mitochondrial Quality Control and Biogenesis in Skeletal Muscle.","date":"2019","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31921843","citation_count":10,"is_preprint":false},{"pmid":"33423297","id":"PMC_33423297","title":"Mss51 deletion increases endurance and ameliorates histopathology in the mdx mouse model of Duchenne muscular dystrophy.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33423297","citation_count":9,"is_preprint":false},{"pmid":"37338036","id":"PMC_37338036","title":"Mss51 protein inhibition serves as a novel target for type 2 diabetes: a molecular docking and simulation study.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/37338036","citation_count":8,"is_preprint":false},{"pmid":"38830447","id":"PMC_38830447","title":"YTHDF2 regulates MSS51 expression contributing to mitochondria dysfunction of granulosa cells in polycystic ovarian syndrome patients.","date":"2024","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38830447","citation_count":7,"is_preprint":false},{"pmid":"37002920","id":"PMC_37002920","title":"Site-1 protease inhibits mitochondrial respiration by controlling the TGF-β target gene Mss51.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37002920","citation_count":6,"is_preprint":false},{"pmid":"34565318","id":"PMC_34565318","title":"Yeast Translational Activator Mss51p and Human ZMYND17 - Two Proteins with a Common Origin, but Different Functions.","date":"2021","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/34565318","citation_count":4,"is_preprint":false},{"pmid":"1523888","id":"PMC_1523888","title":"Analysis of the MSS51 region on chromosome XII of Saccharomyces cerevisiae.","date":"1992","source":"Yeast (Chichester, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1523888","citation_count":3,"is_preprint":false},{"pmid":"40144371","id":"PMC_40144371","title":"Association of two missense mutations in the MSS51 and KAT6B genes with body weight at different ages in cows of the Yaroslavl breed.","date":"2025","source":"Vavilovskii zhurnal genetiki i selektsii","url":"https://pubmed.ncbi.nlm.nih.gov/40144371","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.01.621605","title":"Insights into the Translational Activation Mechanisms of the  <i>COX1</i>  mRNA in Yeast Mitochondria","date":"2024-11-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.01.621605","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10296,"output_tokens":3449,"usd":0.041312,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11201,"output_tokens":3639,"usd":0.07349,"stage2_stop_reason":"end_turn"},"total_usd":0.114802,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"The yeast Mss51 gene product is specifically required for translation of the COX1 mRNA in yeast mitochondria; it is not merely a splicing factor but a translational activator of COX1.\",\n      \"method\": \"Genetic analysis of mss51 mutants; paromomycin-resistance mutation in 15S mitoribosomal RNA interferes with Mss51 action, linking it to the ribosome\",\n      \"journal\": \"Molecular & general genetics : MGG\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational genetic loss-of-function study replicated and built upon by multiple independent labs\",\n      \"pmids\": [\"2177521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Yeast Mss51 has dual functions: it acts as a translational activator of COX1 mRNA (via the 5'-UTR) AND physically associates with newly synthesized, unassembled Cox1 protein in early cytochrome c oxidase assembly intermediates, thereby coupling Cox1 synthesis with CcO assembly. Sequestration of Mss51 in assembly intermediates limits its availability for translation. Cox14 is required for stable interaction of Mss51 with newly synthesized Cox1; without Cox14, Mss51 is not sequestered and Cox1 synthesis is not reduced even when CcO assembly fails.\",\n      \"method\": \"Genetic reporter assays at COX1 locus in mitochondrial DNA; co-immunoprecipitation of Mss51 with Cox1 assembly intermediates; epistasis analysis with cox14 mutants\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, genetic epistasis, reporter assays, replicated by independent labs\",\n      \"pmids\": [\"19710419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cox25 (a new inner mitochondrial membrane protein with matrix-facing hydrophilic C-terminus) is an essential component of the Cox1–Ssc1–Mss51–Cox14 complex that stabilizes newly synthesized Cox1 in yeast. Cox25 also interacts with Shy1 and Cox5 in a separate complex lacking Mss51, suggesting it bridges the Mss51-containing stabilization complex and later CcO assembly intermediates after Ssc1-Mss51 are released.\",\n      \"method\": \"Co-immunoprecipitation of Cox25 with Mss51, Ssc1, Cox14, Cox1; genetic analysis of cox25 null mutants; fractionation showing Cox25 is an intrinsic inner membrane protein\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with multiple partners, genetic epistasis, subcellular fractionation, independent lab confirmation of the Cox1–Mss51 complex\",\n      \"pmids\": [\"21068384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Mammalian MSS51 (ZMYND17) localizes to the mitochondria in human skeletal muscle. CRISPR/Cas9-mediated disruption of Mss51 in C2C12 myoblasts increased cellular ATP levels, β-oxidation, glycolysis, and oxidative phosphorylation, indicating that mammalian Mss51 acts as an inhibitor of mitochondrial metabolism in skeletal muscle. Mss51 expression is upregulated upon myoblast differentiation and is downregulated by myostatin/TGF-β1 inhibition.\",\n      \"method\": \"Subcellular fractionation + immunoblot for localization; CRISPR/Cas9 KO in C2C12 cells; metabolic assays (ATP, β-oxidation, glycolysis, oxidative phosphorylation); qRT-PCR\",\n      \"journal\": \"Journal of neuromuscular diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by fractionation + CRISPR KO with metabolic readouts, single lab, two orthogonal methods\",\n      \"pmids\": [\"26634192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Genetic inactivation of Zmynd17 (MSS51) in mice causes morphological and functional abnormalities in skeletal muscle mitochondria, resulting in decreased respiratory function. Zmynd17 deficiency exacerbates high-fat-diet-induced hepatic steatosis, glucose intolerance, and insulin resistance, and impairs aerobic exercise performance in middle-aged mice, establishing Zmynd17 as a regulator of muscle mitochondrial quality.\",\n      \"method\": \"Genetic KO mouse model; electron microscopy of mitochondrial morphology; mitochondrial respiration assays; metabolic phenotyping (glucose tolerance, insulin tolerance, high-fat diet challenge)\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with multiple orthogonal phenotypic readouts (morphology, respiration, metabolic tests), replicated by independent labs\",\n      \"pmids\": [\"29913553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In vivo deletion of Mss51 in mice increases myofiber oxygen consumption rate, enhances expression of oxidative phosphorylation and fatty acid β-oxidation genes in skeletal muscle, and confers resistance to diet-induced obesity with increased whole-body glucose turnover, glycolysis, insulin sensitivity, and fatty acid β-oxidation, confirming MSS51 as an inhibitor of skeletal muscle mitochondrial respiration and whole-body metabolism.\",\n      \"method\": \"CRISPR/Cas9 KO mouse; Seahorse oxygen consumption rate assay; high-fat diet metabolic challenge; hyperinsulinemic-euglycemic clamp; gene expression profiling\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with multiple orthogonal metabolic assays, independent lab replication of metabolic inhibitory role\",\n      \"pmids\": [\"31527314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Zmynd17-deficient mouse limb muscles show abnormal mitochondrial morphology that is rescued by voluntary exercise, but PGC1α overexpression in Zmynd17-KO muscle further worsens mitochondrial morphology abnormalities (also rescued by exercise). This epistasis indicates that exercise-induced mitochondrial quality control and PGC1α-induced mitochondrial biogenesis operate independently of Zmynd17.\",\n      \"method\": \"Genetic KO mouse; PGC1α overexpression; voluntary exercise intervention; electron microscopy of mitochondrial morphology; epistasis analysis\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo with morphological readout, single lab\",\n      \"pmids\": [\"31921843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Human ZMYND17 deletion in human cells did not affect mitochondrial translation but led to decreased cytochrome c oxidase activity and increased amounts of free F1 subunit of ATP synthase, demonstrating that the human ortholog has diverged from yeast Mss51 and no longer functions as a mitochondrial translational activator.\",\n      \"method\": \"ZMYND17 gene deletion in human cells; measurement of mitochondrial translation products; cytochrome c oxidase activity assay; assessment of ATP synthase F1 subunit\",\n      \"journal\": \"Biochemistry. Biokhimiia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct KO with enzymatic activity assay and protein complex analysis, single lab, two orthogonal methods\",\n      \"pmids\": [\"34565318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Site-1 protease (S1P) is a negative regulator of Mss51 expression in mouse skeletal muscle. S1P disruption reduces Mss51 expression and increases muscle mass and mitochondrial respiration; overexpression of Mss51 in S1P-deficient muscle counteracts the increase in mitochondrial respiration, placing Mss51 downstream of S1P in a TGF-β1 signaling axis that inhibits skeletal muscle mitochondrial respiration.\",\n      \"method\": \"Muscle-specific S1P KO mouse; Mss51 overexpression rescue experiment; mitochondrial respiration assays; gene expression analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with rescue experiment in vivo, single lab, two orthogonal methods\",\n      \"pmids\": [\"37002920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"YTHDF2 binds to MSS51 mRNA (shown by RNA immunoprecipitation) and reduces MSS51 expression in granulosa cells of PCOS patients. Reduction of MSS51 expression leads to mitochondrial damage, reduced ATP levels, increased ROS, and reduced expression of glycolysis genes (LDHA, PFKP, PKM), establishing a YTHDF2→MSS51 regulatory axis controlling mitochondrial function and glycolysis in granulosa cells.\",\n      \"method\": \"RNA immunoprecipitation (RIP) assay demonstrating YTHDF2 binding to MSS51 mRNA; YTHDF2 overexpression and MSS51 knockdown in granulosa cells; ATP/ROS measurement; immunofluorescence; Western blot\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP demonstrating direct mRNA binding, loss-of-function with metabolic readouts, single lab\",\n      \"pmids\": [\"38830447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Betaine transcriptionally represses Mss51 expression via the transcription factor Yin Yang 1 (YY1), which directly binds the Mss51 promoter. In C2C12 cells, betaine restores Mss51-mediated suppression of mitochondrial respiration proteins and attenuates oxygen consumption impairment. In aged mice, AAV-mediated Mss51 overexpression recapitulates mitochondrial dysfunction, confirming Mss51 as a suppressor of mitochondrial respiration regulated by YY1.\",\n      \"method\": \"Luciferase reporter assay; chromatin immunoprecipitation (ChIP); electrophoretic mobility shift assay (EMSA); AAV overexpression in vivo; Seahorse assay; Western blot\",\n      \"journal\": \"Journal of cachexia, sarcopenia and muscle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (ChIP, EMSA, luciferase reporter, in vivo AAV rescue) in single study confirming YY1→Mss51 transcriptional axis\",\n      \"pmids\": [\"39187977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In yeast, Mss51 (like Pet309) stably associates with the mitoribosome independently of the presence of COX1 mRNA or of Pet309, indicating that translational activation of COX1 mRNA involves stable ribosome interaction rather than purely mRNA-dependent recruitment. No direct interaction of Mss51 with COX1 mRNA was detected.\",\n      \"method\": \"Co-purification/co-sedimentation of Mss51 and Pet309 with mitoribosome; genetic experiments removing COX1 mRNA or each activator; domain analysis of Pet309 N-terminal domain\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical ribosome association assay with genetic controls, preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2024.11.01.621605\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"MSS51/ZMYND17 encodes a protein whose yeast ortholog (Mss51p) functions as a COX1 mRNA translational activator that stably associates with the mitoribosome and couples Cox1 synthesis to cytochrome c oxidase assembly by physically interacting with newly synthesized Cox1 in a complex with Cox14, Cox25, and Ssc1—sequestration in this complex limits translation; the mammalian protein (ZMYND17) has diverged from this translational activator role and instead localizes to skeletal muscle mitochondria where it acts as an inhibitor of mitochondrial respiration, β-oxidation, and glycolysis, regulated transcriptionally by the YY1–betaine axis and post-transcriptionally by YTHDF2, and positioned downstream of TGF-β/myostatin/S1P signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MSS51 is a mitochondrial protein whose function has diverged sharply between yeast and mammals while retaining a central role in cytochrome c oxidase (CcO) biology [#0, #3]. In yeast, Mss51 is a translational activator of the mitochondrially encoded COX1 mRNA acting through its 5'-UTR, and it concurrently binds newly synthesized, unassembled Cox1 protein in early CcO assembly intermediates—coupling Cox1 synthesis to assembly such that sequestration of Mss51 in these intermediates limits its availability for further translation [#0, #1]. This Cox1-stabilizing complex includes Cox14, Ssc1, and the inner-membrane protein Cox25, with Cox14 required for stable Mss51–Cox1 association and Cox25 bridging the Mss51-containing complex to later assembly steps involving Shy1 and Cox5 [#1, #2]. The mammalian ortholog (ZMYND17) has lost the translational-activator role—its deletion in human cells does not affect mitochondrial translation but reduces CcO activity—and instead localizes to skeletal-muscle mitochondria where it acts as an inhibitor of mitochondrial respiration, β-oxidation, glycolysis, and oxidative phosphorylation [#3, #7]. In vivo, Mss51 loss enhances myofiber oxygen consumption and oxidative gene expression and confers resistance to diet-induced obesity, insulin resistance, and hepatic steatosis, establishing it as a brake on muscle mitochondrial metabolism and whole-body energetics [#4, #5]. Mss51 expression is controlled transcriptionally by YY1, which directly binds its promoter and is repressed by betaine [#10], and post-transcriptionally by YTHDF2 binding to MSS51 mRNA [#9], and the protein is positioned downstream of TGF-β1/myostatin and Site-1 protease (S1P) signaling that suppresses muscle mitochondrial respiration [#3, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established that the yeast Mss51 gene product is a dedicated translational activator of mitochondrial COX1 mRNA rather than a splicing factor, defining its founding molecular role.\",\n      \"evidence\": \"Genetic analysis of mss51 mutants, with a paromomycin-resistance mutation in 15S mitoribosomal RNA linking Mss51 to the ribosome\",\n      \"pmids\": [\"2177521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the physical partners of Mss51\", \"Mechanism of ribosome engagement not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved how Mss51 couples Cox1 synthesis to assembly by showing it both activates COX1 translation and binds newly made Cox1, with Cox14 required to sequester it and limit further translation.\",\n      \"evidence\": \"Reporter assays at the COX1 locus, co-immunoprecipitation of Mss51 with Cox1 assembly intermediates, and cox14 epistasis in yeast\",\n      \"pmids\": [\"19710419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full subunit composition of the stabilization complex incomplete\", \"Stoichiometry and release mechanism unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified Cox25 as an essential member of the Cox1–Ssc1–Mss51–Cox14 stabilization complex and showed it bridges to later CcO assembly intermediates.\",\n      \"evidence\": \"Reciprocal Co-IP of Cox25 with Mss51, Ssc1, Cox14, Cox1, plus cox25 genetics and fractionation in yeast\",\n      \"pmids\": [\"21068384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Timing of Ssc1–Mss51 release not directly observed\", \"Structural arrangement of the complex unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed the mammalian ortholog acts as a metabolic inhibitor rather than a translational activator, localizing to muscle mitochondria and restraining respiration, β-oxidation, and glycolysis.\",\n      \"evidence\": \"Subcellular fractionation, CRISPR/Cas9 KO in C2C12 myoblasts with ATP, β-oxidation, glycolysis and OXPHOS assays, and qRT-PCR\",\n      \"pmids\": [\"26634192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of metabolic inhibition not defined\", \"Single lab, two orthogonal methods\", \"No direct molecular partners identified in mammals\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established Mss51 as an in vivo regulator of muscle mitochondrial quality whose loss alters mitochondrial morphology and respiration and influences systemic metabolism.\",\n      \"evidence\": \"Zmynd17 KO mouse with electron microscopy, respiration assays, and metabolic phenotyping under high-fat diet\",\n      \"pmids\": [\"29913553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking Mss51 to mitochondrial morphology unclear\", \"Direct molecular target unidentified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Confirmed Mss51 as a brake on muscle mitochondrial respiration and whole-body metabolism, and showed exercise- and PGC1α-driven mitochondrial pathways act independently of it.\",\n      \"evidence\": \"CRISPR KO mice with Seahorse OCR, hyperinsulinemic-euglycemic clamp, high-fat diet challenge, PGC1α overexpression and exercise epistasis\",\n      \"pmids\": [\"31527314\", \"31921843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical mechanism of respiration suppression unresolved\", \"How Mss51 intersects mitochondrial quality control unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated functional divergence of the human ortholog from yeast: its loss does not affect mitochondrial translation but lowers CcO activity and raises free ATP synthase F1.\",\n      \"evidence\": \"ZMYND17 deletion in human cells with measurement of translation products, CcO activity, and ATP synthase F1 assessment\",\n      \"pmids\": [\"34565318\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking ZMYND17 to CcO activity unknown\", \"Single lab\", \"Whether it physically contacts CcO not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined upstream regulators of mammalian Mss51—transcriptional repression by YY1/betaine and post-transcriptional control by YTHDF2—and confirmed its suppression of mitochondrial respiration in vivo.\",\n      \"evidence\": \"ChIP/EMSA/luciferase and AAV overexpression in muscle (YY1/betaine); RNA immunoprecipitation and knockdown in PCOS granulosa cells (YTHDF2)\",\n      \"pmids\": [\"39187977\", \"38830447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How these inputs are integrated in vivo unclear\", \"Direct effector of Mss51 on respiratory machinery still unidentified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed mammalian Mss51 downstream of S1P/TGF-β1 signaling controlling muscle mass and respiration.\",\n      \"evidence\": \"Muscle-specific S1P KO mouse with Mss51 overexpression rescue and respiration assays\",\n      \"pmids\": [\"37002920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between S1P signaling and Mss51 expression not defined\", \"Single lab, rescue-based epistasis\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Refined the yeast translational-activation model by showing Mss51 stably associates with the mitoribosome independently of COX1 mRNA or Pet309, rather than via mRNA-dependent recruitment.\",\n      \"evidence\": \"Co-sedimentation of Mss51 and Pet309 with mitoribosome plus genetic removal of COX1 mRNA/activators (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.11.01.621605\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, single lab\", \"No direct Mss51–COX1 mRNA interaction detected\", \"Structural basis of ribosome binding unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct molecular effector through which mammalian MSS51/ZMYND17 inhibits mitochondrial respiration and metabolism remains undefined.\",\n      \"evidence\": \"No discovery in the corpus identifies a mammalian binding partner or biochemical mechanism for metabolic suppression\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mammalian physical interactor identified\", \"No structural model of the divergent mammalian protein\", \"Mechanistic link between CcO activity change and metabolic phenotype unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [0, 1, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [2, 3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [\"Cox1\\u2013Ssc1\\u2013Mss51\\u2013Cox14\\u2013Cox25 assembly/stabilization complex\", \"mitoribosome (associated)\"],\n    \"partners\": [\"COX1\", \"Cox14\", \"Cox25\", \"Ssc1\", \"Pet309\", \"YY1\", \"YTHDF2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":6,"faith_total":6,"faith_pct":100.0}}